Hi-Tech Pharmacal (HITK) Tops Q2 Earnings Views
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) reports Q2 EPS of $0.09, 3 cents better than the analyst estimate of $0.06. Revenue for the quarter was $25.1 million, versus the consensus of $22.50 million. (only 1 analyst covers the stock)
Hi-Tech Pharmacal Co., Inc. develops, manufactures, markets, and sells generic, prescription, over-the-counter (OTC), and nutritional products in liquid and semisolid dosage forms in the United States.
Hi-Tech Pharmacal Co., Inc. develops, manufactures, markets, and sells generic, prescription, over-the-counter (OTC), and nutritional products in liquid and semisolid dosage forms in the United States.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Infoblox (BLOX) Tops Q3 EPS by 4c; Guides Q4
- Mentor Graphics Corp (MENT) Beats Q1 EPS View by 5c; Lifts FY13 Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
